BACKGROUND: Long-term randomized trials comparing asthma outcomes between inhaled corticosteroids in real-world populations are lacking. As such, rigorously conducted observational studies to complement the findings of randomized trials are needed. OBJECTIVE: We sought to compare asthma-related outcomes over 1 year as recorded in a large primary care database for patients aged 5 to 60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane (HFA)-beclomethasone or fluticasone. METHODS: We used a retrospective matched cohort study in which patients were matched on baseline demographic and disease severity measures. Coprimary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and exacerbation rate. RESULTS: More than 80% of patients in each population achieved asthma control; 10% and 16% of patients in the initiation and step-up populations, respectively, received add-on or combination therapy during the year. Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone for both populations (P <or= .001). In the initiation population (n = 1319 in each cohort) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n = 250) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar between cohorts. CONCLUSIONS: In a real-world setting patients receiving HFA-beclomethasone had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
BACKGROUND: Long-term randomized trials comparing asthma outcomes between inhaled corticosteroids in real-world populations are lacking. As such, rigorously conducted observational studies to complement the findings of randomized trials are needed. OBJECTIVE: We sought to compare asthma-related outcomes over 1 year as recorded in a large primary care database for patients aged 5 to 60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane (HFA)-beclomethasone or fluticasone. METHODS: We used a retrospective matched cohort study in which patients were matched on baseline demographic and disease severity measures. Coprimary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and exacerbation rate. RESULTS: More than 80% of patients in each population achieved asthma control; 10% and 16% of patients in the initiation and step-up populations, respectively, received add-on or combination therapy during the year. Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone for both populations (P <or= .001). In the initiation population (n = 1319 in each cohort) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n = 250) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar between cohorts. CONCLUSIONS: In a real-world setting patients receiving HFA-beclomethasone had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Authors: A Kugelman; M Peniakov; S Zangen; Y Shiff; A Riskin; A Iofe; I Shoris; D Bader; S Arnon Journal: J Perinatol Date: 2016-10-13 Impact factor: 2.521
Authors: David Price; John Haughney; Erika Sims; Muzammil Ali; Julie von Ziegenweidt; Elizabeth V Hillyer; Amanda J Lee; Alison Chisholm; Neil Barnes Journal: J Asthma Allergy Date: 2011-04-28
Authors: David Price; Alison Chisholm; Thys van der Molen; Nicolas Roche; Elizabeth V Hillyer; Jean Bousquet Journal: Curr Allergy Asthma Rep Date: 2011-12 Impact factor: 4.806
Authors: David Price; Henry Chrystyn; Alan Kaplan; John Haughney; Miguel Román-Rodríguez; Annie Burden; Alison Chisholm; Elizabeth V Hillyer; Julie von Ziegenweidt; Muzammil Ali; Thys van der Molen Journal: Allergy Asthma Immunol Res Date: 2012-04-06 Impact factor: 5.764
Authors: Steve W Turner; Kathryn Richardson; Annie Burden; Mike Thomas; Clare Murray; David Price Journal: NPJ Prim Care Respir Med Date: 2015-06-11 Impact factor: 2.871
Authors: Claudio Terzano; Giovanni Cremonesi; Giuseppe Girbino; Eleonora Ingrassia; Serafino Marsico; Gabriele Nicolini; Luigi Allegra Journal: Respir Res Date: 2012-12-06